Quantitative interpretation of PF4/heparin-EIA optical densities in predicting platelet-activating VITT antibodies.

Background: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a prothrombotic, heparin-induced thrombocytopenia (HIT)-mimicking, adverse reaction caused by platelet-activating anti-platelet factor 4 (PF4) antibodies that occurs rarely after adenovirus vector-based COVID-19 vaccination. Strength of PF4-dependent enzyme immunoassay (EIA) reactivity-judged by optical density (OD) measurements-strongly predicts platelet-activating properties of HIT antibodies in a functional test. Whether a similar relationship holds for VITT antibodies is unknown.

Clinical evaluation of cefazedone.

The results of clinical trials with (6R,7R)-7-(2-[3,5-dichloro-4-oxo-1(4H)-pyridyl]-acetamido)-3-([(5-methyl-1,3,4-thiadiazol-2-yl)-thio]methyl)-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid (cefazedone, Refosporen), a new cephalosporin derivative, are reported. Overall clinical assessment in a variety of indications, including urinary tract infections, respiratory tract infections, biliary tract and other abdominal infections, surgical and dermatological infections, gynaecological infections, on 699 patients showed very good and good results in 90.5% of patients.